Aarti Pharmalabs Holds 7th AGM: Declares ₹2 Dividend, Approves Director Changes
Aarti Pharmalabs Limited held its 7th AGM on September 22, 2026. The company declared a final dividend of ₹2 per equity share for FY26. Key management changes include Smt. Hetal Gogri Gala moving to Whole-time Director and Shri. Rashesh C. Gogri becoming Managing Director, both effective October 1, 2026. Financial statements for FY26 were adopted.
The declaration of dividend and changes in directorships are material events for shareholders and the company's governance structure.
The AGM approved a dividend payout and significant management role changes, indicating positive corporate actions and continuity.
Aarti Pharmalabs Limited conducted its 7th Annual General Meeting (AGM) on Tuesday, September 22, 2026, commencing at 11:00 a.m. IST, via Video Conferencing (VC) / Other Audio Visual Means (OAVM).
The meeting addressed several key agenda items including the adoption of Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. Shareholders approved a final dividend of ₹2 per Equity Share of Face Value of ₹5 each for the said financial year. Additionally, ordinary business included the non-re-appointment of Director Shri Rajendra Gogri. Special business involved the ratification of remuneration for Cost Auditors for the financial year ending March 31, 2027. Significant changes in designations were approved: Smt. Hetal Gogri Gala's designation changed from Managing Director to Whole-time Director effective October 1, 2026, and Shri. Rashesh C. Gogri's designation changed from Non-Executive Director to Managing Director, also effective October 1, 2026.
The Chairman, Shri Rashesh C. Gogri, presented a brief speech updating shareholders on the company's financial performance and major accomplishments, along with an overview of ongoing projects. The Chief Financial Officer, Shri Piyush Lakhani, provided a detailed overview of the company's performance for the financial year ended March 31, 2026. Shareholders had the opportunity to ask questions and express their views, which were addressed by the Chairman and Vice-Chairperson and Managing Director. Remote e-voting commenced on September 19, 2026, and concluded on September 21, 2026, with electronic voting also available during the AGM. The results of the voting will be declared within two working days upon receipt of the Scrutinizer's Report and will be posted on the company's website and stock exchanges.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.